[English]  [Pусский]  [中文]  
ctt-journal > Ivolgin D.1 et al. (Abstract)

Ivolgin D.1 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract83

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment


Umbilical cord blood processing: quality evolution in course of inclusion criteria optimization

Dmitry A. Ivolgin, Ksenia V. Korovina, Ksenia V. Shunkina, Alexander B. Smolyaninov

Research laboratory of cell technologies of the North-Western State Medical University named after I. I. Mechnikov, St. Petersburg, Russia; "Stem Cell Bank Pokrovsky", St. Petersburg, Russia

Correspondence: Alexander B. Smolyaninov, "Stem Cell Bank Pokrovsky", Bolshoi Prospect Vasilevski Ostrov 85, St. Petersburg, 199106, Russia, E-mail: stemcellbank@spam is badinbox.ru


Aim: To set out and to substantiate the inclusion criteria for umbilical cord blood (UCB) entering a stem cell bank for the purposes of obtaining UCB stem cell (SC) units suitable for transplantation for hematological malignances.

Methods: We conducted a retrospective analysis of the quality characteristics of UCB units (n=961). All the units were processed in the Pokrovski Stem Cell Bank with automatic methods (Sepax S-100, Biosafe, Switzerland), and divided to 2 groups: those that had been processed before 01.12.2009, the date that the inclusion criteria (min. volume of UCB suitable for processing) changed from 40 ml to 80 ml (n= 398) (Group No. 1), and after 01.12.2009 (n=563) (Group No. 2). Nuclear cell (NC) count was measured with a hematology analyzer ("ACT diff 2", Beckman Coulter, USA), and the CD34+/CD45+ cell count and viability were determined by flow cytometry (Cytomix FC500, Beckman Coulter, USA) in both groups.

Results: The mean recovery of nuclear cells in Groups 1 and 2 was 57.22±0.81% and 81.12±0.33%, respectively; mean viability in Groups 1 and 2 was 98.34±0.26% and 98.46±0.12%, respectively, and mean CD34/45+ count in Groups 1 and 2 was 2.14±0.13 х 106 and 4.08±0.12 х106, respectively.

Conclusions: The data shows that the UCB inclusion criteria changing led to a significant increase in NC recovery and the absolute CD34+ count per UCB unit without any changes of viability. Such an increase in recovery due is apparently to the technological features of the Sepax S-100 apparatus, which for a given volume of concentrate and insufficient numbers of cells dilutes the buffy coat with the plasma. Thus, determination of the minimum volume of UCB entering to the stem cells bank as suitable for further processing — 80 ml — allows the obtaining of a hematopoietic stem cell concentrate suitable for transplantation for hematological diseases with a high degree of efficiency.

Keywords: cord blood processing, Sepax S-100 apparatus, transplantation of stem cells, inclusions criteria for UCB processing